Patented biomarker for cardiac injury.
Patented biomarker for cardiac injury.
St Thomas’ and Guy’s NHS Foundation Trust in UK have 840 beds, 218,000 emergency/urgent care attendances and are testing 7,800 patients per year for troponin. If high sensitivity Troponin I is replaced by cMyC on the central lab platform, the immediate discharge would increase from 15% to 32%. With this increase in discharged patients at first blood draw, they calculated that the below costs and bed-days could be saved[1,2,3,4].
NHS in the UK estimates to have around 25 million emergency admissions per year[5].
Applying the above assumption and calculation related to 25M instead of 218K emergency admissions per year would result in the following cost savings.
In the US, the CDC has calculated that there are 130 million emergency admissions per year (2018) [6].
Applying the above assumption and calculation related to 130M instead of 218K emergency admissions per year would result in the following cost savings every year.
Imprint: KDx Acceleration, 38 rue de Berri, 75008 Paris, France
© Copyright 2021-2025 KDx Acceleration. All rights reserved.
© Copyright 2021-2025 KDx Acceleration. All rights reserved.